Sarepta Therapeutics (SRPT) PT Raised to $176 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $18.99 +2.43%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $176.00 (from $164.00) while maintaining a Buy rating.
You May Also Be Interested In
- Bayerische Motoren Werke AG (BMW:GR) (BMWYY) PT Lowered to EUR66 at HSBC
- Zimmer Biomet (ZBH) PT Raised to $125 at Stifel
- Expedia (EXPE) PT Raised to $320 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
